Innoviva's Composite Rating Surges to 96, Solidifying Its Status as a Top Performer

Innoviva's IBD SmartSelect Composite Rating rose to 96, up from 93, placing it in the top 4% of all stocks. This indicates strong performance and technical strength. The biotech stock joins an elite group of stocks with a 95-plus composite rating, which often correlates with the market's biggest winners in the early stages of a new trend.